Human Anti-FLT1 Recombinant Antibody (clone 6F9) (CAT#: HPAB-1702-FY)

Figure 1 A chart depicts the results of an ELISA-based binding assay measuring in vitro binding activity of embodiments of anti-VEGFR-I antibodies to VEGFR-I.

Figure 2 A chart depicts the results of an ELISA-based blocking assay measuring in vitro competition of embodiments of anti-VEGFR-I antibodies with P1GF for VEGFR-I binding.

Figure 3 A chart depicts the results of an ELISA-based blocking assay measuring in vitro competition of embodiments of anti-VEGFR-I antibodies with VEGF for VEGFR-I binding.

Figure 4 Shows the results of flow cytometry analysis showing binding reactivity of embodiments of anti-VEGFR-I antibodies with VEGFR-I expressing porcine aorta endothelial cells.

Figure 5 Shows a dose response curve showing the inhibition of VEGF stimulated cell proliferation in DU4475 breast carcinoma cells treated with embodiments of anti-VEGFR-I antibodies in a dose response manner.

Figure 6 Shows a chart plotting tumor growth of DU4475 (FIG. 25A) and MDA-MB-435 (FIG. 25B) breast tumors versus days after treatment with anti-VEGFR-I antibodies 18F1, 6F9 and 15F11.